+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Meningococcal disease: the advances and challenges of meningococcal disease prevention

Meningococcal disease: the advances and challenges of meningococcal disease prevention

Human Vaccines 7(8): 828-837

Vaccination as a means to prevent meningococcal disease caused by Neisseria meningitidis is critical given the abrupt onset and rapid progression of this disease. Five serogroups--A, B, C, W-135, and Y--are responsible for the majority of cases. In developed countries, infants have the greatest risk of disease, with a smaller secondary peak observed in late adolescence. Vaccines utilizing the polysaccharide capsule are poorly immunogenic in young children but can reduce the incidence of meningococcal carriage in high risk groups. In contrast, protein conjugate vaccines to polysaccharide capsules A, C, W-135, and Y have broadened the population protection from disease but their effect on meningococcal carriage and transmission is yet unknown except for monovalent meningococcal C conjugate that has been shown to reduce carriage. Challenges remain in providing direct protection to infants and protection against meningococcal B disease. To date, outer membrane vesicle vaccines have been used to control meningococcal B disease in epidemic settings and vaccine candidates against subcapsular antigens are in development, but a vaccine that confers long-lasting protection is unavailable.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054327154

Download citation: RISBibTeXText

PMID: 21832882

DOI: 10.4161/hv.7.8.16270

Related references

Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges. Human Vaccines and Immunotherapeutics 14(5): 1107-1115, 2018

New guidelines for management and prevention of meningococcal disease in Australia. Meningococcal Disease Working Party of the National Health and Medical Research Council. Medical Journal of Australia 166(11): 598-601, 1997

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease. Therapeutics and Clinical Risk Management 4(4): 739-745, 2008

Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 116(2): 496-505, 2005

Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine. Annals of PharmacoTherapy 40(4): 666-673, 2006

Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. Epidemiology and Infection 142(9): 2000-2012, 2014

Advances towards the prevention of meningococcal B disease: a multidimensional story. Journal of Infection 68(Suppl. 1): S76-S82, 2014

Successes and Remaining Challenges in Meningococcal Disease Prevention. Pediatric Research 68: 3-4, 2010

Prognostic markers of meningococcal disease in children: recent advances and future challenges. Expert Review of Anti-Infective Therapy 12(11): 1357-1369, 2014

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Review of Vaccines 18(1): 15-30, 2019

Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review. Epidemiology and Infection 143(11): 2259-2268, 2015

Prognostic factors in meningococcal disease. Development of a bedside predictive model and scoring system. Barcelona Meningococcal Disease Surveillance Group. JAMA 278(6): 491-496, 1997

Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease. Journal of Clinical Microbiology 40(5): 1834-1837, 2002

Meningococcal disease in the United States--1986. Meningococcal Disease Study Group. Journal of Infectious Diseases 164(2): 368-374, 1991

Guidelines for control of meningococcal disease. Laboratory Centre for Disease Control. Canadian Consensus Conference on Meningococcal Disease. Cmaj 150(11): 1825-1839, 1994